Measuring financial toxicity as a clinically relevant patient‐reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST)
Top Cited Papers
Open Access
- 7 October 2016
- Vol. 123 (3), 476-484
- https://doi.org/10.1002/cncr.30369
Abstract
Cancer and its treatment lead to increased financial distress for patients. To the authors’ knowledge, to date, no standardized patient-reported outcome measure has been validated to assess this distress. Patients with AJCC Stage IV solid tumors receiving chemotherapy for at least 2 months were recruited. Financial toxicity was measured by the COmprehensive Score for financial Toxicity (COST) measure. The authors collected data regarding patient characteristics, clinical trial participation, health care use, willingness to discuss costs, psychological distress (Brief Profile of Mood States [POMS]), and health-related quality of life (HRQOL) as measured by the Functional Assessment of Cancer Therapy: General (FACT-G) and the European Organization for Research and Treatment of Cancer (EORTC) QOL questionnaires. Test-retest reliability, internal consistency, and validity of the COST measure were assessed using standard-scale construction techniques. Associations between the resulting factors and other variables were assessed using multivariable analyses. A total of 375 patients with advanced cancer were approached, 233 of whom (62.1%) agreed to participate. The COST measure demonstrated high internal consistency and test-retest reliability. Factor analyses revealed a coherent, single, latent variable (financial toxicity). COST values were found to be correlated with income (correlation coefficient [r] = 0.28; P<.001), psychosocial distress (r = -0.26; P<.001), and HRQOL, as measured by the FACT-G (r = 0.42; P<.001) and by the EORTC QOL instruments (r = 0.33; P<.001). Independent factors found to be associated with financial toxicity were race (P = .04), employment status (P<.001), income (P = .003), number of inpatient admissions (P = .01), and psychological distress (P = .003). Willingness to discuss costs was not found to be associated with the degree of financial distress (P = .49). The COST measure demonstrated reliability and validity in measuring financial toxicity. Its correlation with HRQOL indicates that financial toxicity is a clinically relevant patient-centered outcome. Cancer 2016. © 2016 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society.Keywords
This publication has 21 references indexed in Scilit:
- Association of Financial Strain With Symptom Burden and Quality of Life for Patients With Lung or Colorectal CancerJournal of Clinical Oncology, 2016
- Financial Insolvency as a Risk Factor for Early Mortality Among Patients With CancerJournal of Clinical Oncology, 2016
- Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot studyThe Lancet Haematology, 2015
- Population-Based Assessment of Cancer Survivors' Financial Burden and Quality of Life: A Prospective Cohort StudyJournal of Oncology Practice, 2015
- The development of a financial toxicity patient‐reported outcome in cancer: The COST measureCancer, 2014
- Patient-Oncologist Cost Communication, Financial Distress, and Medication AdherenceJournal of Oncology Practice, 2014
- The Financial Toxicity of Cancer Treatment: A Pilot Study Assessing Out-of-Pocket Expenses and the Insured Cancer Patient's ExperienceThe Oncologist, 2013
- Psychosocial Care for Family Caregivers of Patients With CancerJournal of Clinical Oncology, 2012
- Association Between Prescription Co-Payment Amount and Compliance With Adjuvant Hormonal Therapy in Women With Early-Stage Breast CancerJournal of Clinical Oncology, 2011
- Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidanceHealth and Quality of Life Outcomes, 2006